Indication
Hematopoietic syndrome of acute radiation syndrome
Hematopoietic syndrome of acute radiation syndrome is a life-threatening, dose-dependent clinical sub-syndrome caused by high-dose, penetrating ionizing radiation delivered to the whole body or a significant portion of it over a short duration. Read more about Hematopoietic syndrome of acute radiation syndrome
26 drugs 14 manufacturers
Drugs that treat it
Common Hematopoietic syndrome of acute radiation syndrome therapies.
LEUKINE (sargramostim)
RELEUKO (filgrastim-ayow)
RELEUKO (filgrastim-ayow)
FYLNETRA (pegfilgrastim-pbbk)
STIMUFEND (pegfilgrastim-fpgk)
UDENYCA AUTOINJECTOR (pegfilgrastim-cbqv)
UDENYCA ONBODY (pegfilgrastim-cbqv)
UDENYCA (pegfilgrastim-cbqv)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonHematopoietic syndrome of acute radiation syndrome is a life-threatening, dose-dependent clinical sub-syndrome caused by high-dose, penetrating ionizing radiation delivered to the whole body or a significant portion of it over a short duration.
It primarily targets the hematopoietic system, driven pathophysiologically by the profound depletion and mitotic arrest of radiosensitive bone marrow hematopoietic stem and progenitor cells.
This myelosuppression results in severe pancytopenia characterized by profound lymphopenia, neutropenia, and thrombocytopenia, which typically manifests weeks after exposure with life-threatening infections, sepsis, spontaneous hemorrhage, and impaired wound healing.
- cdc.gov
Hematopoietic syndrome of acute radiation syndrome is a life-threatening, dose-dependent clinical sub-syndrome caused by high-dose, penetrating ionizing radiation delivered to the whole body or a significant portion of it over a short duration It primarily targets the hematopoietic system, driven pathophysiologically by the profound depletion and mitotic arrest of radiosensitive bone marrow hematopoietic stem and progenitor cells
- fda.gov
Hematopoietic syndrome of acute radiation syndrome is a life-threatening, dose-dependent clinical sub-syndrome caused by high-dose, penetrating ionizing radiation delivered to the whole body or a significant portion of it over a short duration
- nih.gov
It primarily targets the hematopoietic system, driven pathophysiologically by the profound depletion and mitotic arrest of radiosensitive bone marrow hematopoietic stem and progenitor cells
- nih.gov
This myelosuppression results in severe pancytopenia characterized by profound lymphopenia, neutropenia, and thrombocytopenia, which typically manifests weeks after exposure with life-threatening infections, sepsis, spontaneous hemorrhage, and impaired wound healing
- nrc.gov
This myelosuppression results in severe pancytopenia characterized by profound lymphopenia, neutropenia, and thrombocytopenia, which typically manifests weeks after exposure with life-threatening infections, sepsis, spontaneous hemorrhage, and impaired wound healing
Personalize your experience
Follow Hematopoietic syndrome of acute radiation syndrome and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.